Literature DB >> 20099030

Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program.

Robert J Constantine1, Ross Andel, Rajiv Tandon.   

Abstract

We studied trends in antipsychotic polypharmacy over a 4 year period in order to see if a change occurred when a statewide quality improvement program aimed at reducing the practice was implemented. Antipsychotic polypharmacy prevalence rates were calculated for eight 6-month periods for enrollees with schizophrenia and schizoaffective disorder and for those with all other diagnoses. Prevalence increased from 1/2003 to 12/2004 and then declined for 4 successive 6 month periods beginning in the 1/2005-6/05 period when the program began. Piecewise linear regression results for both diagnostic groups confirmed that the change in the likelihood of antipsychotic polypharmacy during the four 6 month periods before program implementation were significantly different than during the four 6 month periods following implementation. While it is impossible to control for the effects of all variables in evaluating the impact of any system wide intervention the data suggest that the program did help to reduce the use of antipsychotic polypharmacy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20099030     DOI: 10.1007/s10597-009-9288-2

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  40 in total

1.  Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution.

Authors:  R M Procyshyn; N B Kennedy; G Tse; B Thompson
Journal:  Can J Psychiatry       Date:  2001-05       Impact factor: 4.356

2.  Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region.

Authors:  Ellen M Weissman
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

3.  Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.

Authors:  Kang Sim; Alex Su; Senta Fujii; Shu-Yu Yang; Mian-Yoon Chong; Gabor S Ungvari; Tianmei Si; Eun K Chung; Hin-Yeung Tsang; Yiong H Chan; Stephan Heckers; Naotaka Shinfuku; Chay H Tan
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 4.  Practice guideline for the treatment of patients with schizophrenia, second edition.

Authors:  Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

Review 5.  Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature.

Authors:  Constantin Tranulis; Leila Skalli; Pierre Lalonde; Luc Nicole; Emmanuel Stip
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  Antipsychotic polypharmacy does not increase the risk for side effects.

Authors:  Soma Ganesan; Ross Taylor; Kiran Rabheru; Ian Forbes; Jane Dumontet; Ric M Procyshyn
Journal:  Schizophr Res       Date:  2007-10-22       Impact factor: 4.939

7.  Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.

Authors:  Todd P Gilmer; Christian R Dolder; David P Folsom; William Mastin; Dilip V Jeste
Journal:  Psychiatr Serv       Date:  2007-07       Impact factor: 3.084

Review 8.  When is antipsychotic polypharmacy supported by research evidence? Implications for QI.

Authors:  Jessica L Gören; Joseph J Parks; Frank A Ghinassi; Celeste G Milton; John M Oldham; Pablo Hernandez; Jeffrey Chan; Richard C Hermann
Journal:  Jt Comm J Qual Patient Saf       Date:  2008-10

9.  Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Kenji F Tanaka; Masayuki Tomita; Kenichi Tsunoda; Kensuke Nomura; Harumasa Takano; Akira Tanabe; Koichiro Watanabe; Gohei Yagi; Haruo Kashima
Journal:  Int Clin Psychopharmacol       Date:  2003-11       Impact factor: 1.659

10.  Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.

Authors:  D Elie; M Poirier; Jm Chianetta; M Durand; Ca Grégoire; S Grignon
Journal:  J Psychopharmacol       Date:  2009-01-22       Impact factor: 4.153

View more
  8 in total

1.  Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial.

Authors:  Reinhold Kilian; Tilman Steinert; Wiltrud Schepp; Prisca Weiser; Susanne Jaeger; Carmen Pfiffner; Karel Frasch; Gerhard W Eschweiler; Thomas Messer; Daniela Croissant; Thomas Becker; Gerhard Längle
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-04-22       Impact factor: 5.270

Review 2.  Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Authors:  Thomas R E Barnes; Carol Paton
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

3.  Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis.

Authors:  Mahin Delara; Lauren Murray; Behnaz Jafari; Anees Bahji; Zahra Goodarzi; Julia Kirkham; Mohammad Chowdhury; Dallas P Seitz
Journal:  BMC Geriatr       Date:  2022-07-19       Impact factor: 4.070

4.  Factors associated with non evidence-based prescribing of antipsychotics.

Authors:  Anne Connolly; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

5.  Validation of a claims-based antipsychotic polypharmacy measure.

Authors:  Emily Leckman-Westin; Edith Kealey; Nitin Gupta; Qingxian Chen; Tobias Gerhard; Stephen Crystal; Mark Olfson; Molly Finnerty
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-03-24       Impact factor: 2.890

6.  Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy.

Authors:  Robert O Cotes; David R Goldsmith; Sarah L Kopelovich; Cathy A Lally; Benjamin G Druss
Journal:  Community Ment Health J       Date:  2017-11-10

7.  Significance and Factors Associated with Antipsychotic Polypharmacy Utilization Among Publicly Insured US Adults.

Authors:  Marcela Horvitz-Lennon; Rita Volya; Katya Zelevinsky; Mimi Shen; Julie M Donohue; Andrew Mulcahy; Sharon-Lise T Normand
Journal:  Adm Policy Ment Health       Date:  2021-05-19

8.  Antipsychotic Medication Prescribing Practices Among Adult Patients Discharged From State Psychiatric Inpatient Hospitals.

Authors:  Glorimar Ortiz; Vera Hollen; Lucille Schacht
Journal:  J Psychiatr Pract       Date:  2016-07       Impact factor: 1.325

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.